Phaseline

Targets › FGFR

FGFR: drug programs, companies and trials

5 programs from 5 companies in 5 trials: 4 Phase 2, 1 Phase 1; Oncology, Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: the race on FGFR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jiangxi Provincial Cancer HospitalAnlotinib hydrochloride
Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, RET, KIT)
VEGFR, FGFR, RET, KITPhase 2Esophageal Squamous Cell CarcinomaNov 2026
University of UtahXL092 (Zanzalintinib)
Multi-target kinase inhibitor targeting FGFR, VEGFR, and KIT
FGFR, VEGFR, KITPhase 2Metastatic Castration-resistant Prostate CancerDec 2026
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAnlotinib hydrochloride
Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR inhibitor)
VEGFR, FGFR, PDGFRPhase 2Sarcoma,Soft TissueDec 2027
Eye & ENT Hospital of Fudan UniversityAnlotinib Hydrochloride
Multi-target tyrosine kinase inhibitor
VEGFR, FGFR, RET, KITPhase 2Adenoid Cystic CarcinomaJun 2028
Peking University First HospitalDonor NK cells injection
Non-genetically modified natural killer cells therapy
FGFRPhase 1Acute Myeloid Leukemia (AML)Dec 2026

Conditions

Acute Myeloid Leukemia (AML) (1) Esophageal Squamous Cell Carcinoma (1) Metastatic Castration-resistant Prostate Cancer (1) Adenoid Cystic Carcinoma (1) Sarcoma,Soft Tissue (1)

Modalities

small molecule (4), other (1)

Companies

Peking University First Hospital (1) Jiangxi Provincial Cancer Hospital (1) University of Utah (1) Eye & ENT Hospital of Fudan University (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)

Related targets

VEGFR (4) KIT (3) RET (2) PDGFR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.